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DOI 10.1016/j.ccr.2010.11.011SUMMARYNeoantigens derived from somatic mutations in tumors may provide a critical link between the adaptive
immune system and cancer. Here, we describe a system to introduce exogenous antigens into genetically
engineered mouse lung cancers to mimic tumor neoantigens. We show that endogenous T cells respond
to and infiltrate tumors, significantly delaying malignant progression. Despite continued antigen expression,
T cell infiltration does not persist and tumors ultimately escape immune attack. Transplantation of cell lines
derived from these lung tumors or prophylactic vaccination against the autochthonous tumors, however,
results in rapid tumor eradication or selection of tumors that lose antigen expression. These results provide
insight into the dynamic nature of the immune response to naturally arising tumors.INTRODUCTION
The potential for functionally important interactions between
a developing tumor and the immune system has been appreci-
ated for over a century. The association of tumor cells and
lymphocytes has led researchers to postulate that the immune
system actively inhibits the formation and progression of trans-
formed cells and ultimately ‘‘shapes’’ nascent tumors by forcing
the selective evolution of tumor cells that can evade the immune
response, a phenomenon called tumor immunoediting (Dunn
et al., 2002). Significant numbers of T cells specific to mutated
tumor proteins have been identified in cancer patients (Finn,
2008; Novellino et al., 2005; Parmiani et al., 2007; Rubio et al.,
2003), and several studies have correlated immune infiltration
in tumors with improved prognosis (Buckanovich et al., 2008;
Budhu et al., 2006; Finak et al., 2008; Galon et al., 2006; Moll-
drem et al., 2000; Pages et al., 2005; Piersma et al., 2007).Significance
Our immune system may naturally protect us from cancer by
study of immune-tumor interactions has relied upon T cell resp
expressed from transgenic mouse cancer models. Here, we re
endogenously arising lung tumors expressing exogenous an
differences in theway that the immune system responds to tum
transplanted tumor cell lines. Rather than eliminate tumors, T
patients. This model provides a valuable system for the optim
72 Cancer Cell 19, 72–85, January 18, 2011 ª2011 Elsevier Inc.However, the persistence of malignant disease despite immune
recognition presents an important medical and therapeutic
question: how do tumors escape immune surveillance?
Several mouse models have been used to gain insights into
the mechanisms by which tumors may subvert immune
responses, but each of these has critical limitations. Transplan-
tation of primary or cultured tumor cells is commonly used, but
these models are limited because they ectopically introduce
large numbers of fully developed tumor cells that grow rapidly,
and transplantation can initiate proinflammatory responses
or traffic tumor cells directly to lymphoid organs (Khong and
Restifo, 2002; Ochsenbein et al., 2001; Spiotto et al., 2002).
Carcinogen-induced models have focused predominantly on
sarcomas rather than cancers of epithelial origin and these
tumors are expected to harbor large numbers of mutations that
may lead to artificially robust immune responses (Dunn et al.,
2002; Khong and Restifo, 2002). Transgenic mouse modelsrecognizing and eliminating nascent tumors. However, the
onses to transplanted tumors or tumor-associated antigens
port a system to assess how T cells respond and adapt to
tigens that model tumor neoantigens. We uncover critical
ors that originate from transformation of somatic cells versus
cells suppress tumor progression, reflecting data in cancer
ization of immune therapies to eradicate human cancers.
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Figure 1. Induction of Lung Tumors Using Lentiviral Vectors
(A) Design of Lenti-x and Lenti-LucOS (SIN-LTR: self-inactivating long terminal repeat, c: HIV packaging signal, cPPT: central polypurine tract, PGK: phospho-
glycerate kinase promoter, WRE: woodchuck posttranscriptional regulatory element, UbC: ubiquitin C promoter).
(B) Lung tumors induced with Lenti-x or Lenti-LucOS were stained with H&E, anti-CD3, or anti-B220, 8 weeks after tumor initiation. Scale = 50 mm (inset 10 mm).
(C and D) Quantification of immune infiltrates by IHC for CD3 and B220 8 and 16 weeks post tumor initiation. p values are108 and103 for CD3, and1015
and 0.02 for B220 at 8 and 16 weeks, respectively. n = 2–5 mice, 16–100 tumors, per group.
(E) Percentage of lung tumors/mouse containing infiltrating lymphocytes at 8, 16, and 24 weeks after tumor initiation. n = 9–22 mice, 49–1594 tumors, per group.
Data are mean ± SEM. See also Figure S1.
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Endogenous T Cell Responses to Lung Adenocarcinomaof cancer that develop tumors spontaneously and express
model tumor antigens throughout targeted organs fail to fully
recapitulate immune responses against the human disease
because antigen expression in normal tissues likely alters the
T cell response, and thymic deletion of antigen-specific T cells
typically prevents the study of endogenous T cell responses to
tumors (Bai et al., 2008; Drake et al., 2005; Getnet et al., 2009;
Lyman et al., 2004; Muller-Hermelink et al., 2008; Nguyen
et al., 2002; Savage et al., 2008; Smith et al., 1997; Speiser
et al., 1997). Furthermore, as transgenic models rely on sporadic
tumor-initiating events that can vary widely from tumor to tumor
and mouse to mouse (Frese and Tuveson, 2007), it is difficult to
follow the dynamics of the T cell response over time.
In contrast, genetically engineered mouse models of many
human cancers accurately recapitulate both the genetic and histo-
pathologic progression of the human disease from its earliest
lesions to metastasis and can provide spatiotemporal control of
tumor onset (Frese and Tuveson, 2007). However, few studies
have employed these models to elucidate the interplay between
tumors and the immune system (Cheung et al., 2008; Clark et al.,
2007; Huijbers et al., 2006; Willimsky and Blankenstein, 2005).
This is especially true in the context of lung cancer,which is respon-
sible for more than one million deaths each year worldwide. In
an effort to investigate the effect of T cell responses againsttumor-specific antigens on tumor progression, we developed
a system to induce potentially immunogenic autochthonous lung
adenocarcinomas in a genetically engineered mouse model of the
disease.
RESULTS
Autochthonous Lung Tumors Expressing Tumor
Antigens Are Infiltrated by Lymphocytes
Early during Tumor Development
To generate autochthonous lung tumors in a spatiotemporally
controlled fashion, we utilized a model of human lung adenocar-
cinoma driven by the conditional expression of oncogenic
K-rasG12D in combination with the loss of p53 (DuPage et al.,
2009; Jackson et al., 2001, 2005). Tumor formation was initiated
in K-rasLSL-G12D/+;p53fl/fl mice by inhalation of lentiviral vectors
expressing Cre recombinase. To induce tumors that lack expres-
sion of model antigens, we used a lentiviral vector expressing
Cre alone (Lenti-x, Figure 1A). These tumors exhibited little to
no lymphocyte infiltration throughout their development as
assessed by hematoxylin and eosin (H&E) staining and immuno-
histochemistry (Figures 1B–1E). To induce tumors that express
model tumor antigens, we engineered lentiviral vectors that, in
addition to Cre, express the T cell antigens SIYRYYGL (SIY)Cancer Cell 19, 72–85, January 18, 2011 ª2011 Elsevier Inc. 73
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Endogenous T Cell Responses to Lung Adenocarcinomaand two antigens from ovalbumin – SIINFEKL (SIN, OVA257-264)
and OVA323-339 – fused to the C terminus of luciferase, enabling
us to monitor antigen expression in tumors (Lenti-LucOS,
Figure 1A). As shown in Figure 1, Lenti-LucOS-induced tumors
had large numbers of infiltrating lymphocytes including both T
and B cells at 8 weeks after tumor initiation (Figures 1B–1E).
There were no differences in innate immune cell infiltrates
between tumor types (see Figure S1 available online).
T Cell Responses against Tumor Antigens
Are Generated but Not Maintained
To examine the T cell response to LucOS expression in tumors
over time, we assessed the degree of T cell infiltration at 16
and 24 weeks after tumor initiation. In contrast to the robust
lymphocytic infiltration of Lenti-LucOS tumors8weeks after tumor
initiation, there was a dramatic reduction in tumor-infiltrating
lymphocytes at later time points, indicating that the immune
response was not sustained or tumors had escaped (Figures
1C–1E). We performed flow cytometry with MHCI/Kb DimerX
reagents loaded with SIY or SIN peptides to determine whether
T cell infiltrates were specific for the model antigens. At several
time points after tumor initiation with Lenti-LucOS, we detected
CD8+ T cells reactive to SIY/Kb and SIN/Kb in the lungs and the
mediastinal lymph nodes draining the lungs (DLN) (Figure 2A). As
a control for robust T cell responses to the same antigens in the
same organ, we infected mice with a recombinant influenza virus
engineered to express SIY (WSN-SIY, Figure 2A). The antigen-
specific T cell response to Lenti-LucOS tumors peaked between
4 and 8 weeks after tumor initiation but declined thereafter in the
lungs and DLN, whereas T cells responding to SIY expressed
by influenza expanded and contracted rapidly in the lungs (within
2–4 weeks) and persisted in the DLN (Figures 2B and 2C; Figures
S2A and S2B).We hypothesize that the delayed T cell response to
tumors was due to relatively low levels of antigen produced and
presented in the lung DLNs early during tumor development. To
further investigate the early response, we analyzed the T cell
response after Lenti-LucOS introduction into the lungs of mice
that lacked the K-rasLSL-G12D allele and could not form tumors
(Figures S2C–S2H). We found that SIY and SIN-specific T cells
were generated in the absence of tumor formation, presumably
due to antigen expression in normal cells of the lung (Figures
S2I–S2K). This indicates that while antigen expression is largely
restricted to tumors in this system, the lentiviral infection can stim-
ulate antigen-specific T cells that may contribute to the ensuing
antitumor T cell response. Importantly, however, the T cell
response in the absence of transformation was weak and short-
lived when compared with mice that generated tumors (Fig-
ures S2C–S2H). This may indicate that the immune system
respondsdifferently to transformedcells or that tumor proliferation
within the first several days following K-rasG12D activation leads to
greater antigen production and, hence, more T cell activation.
Endogenous Tumor-Reactive T Cells Are Not Fully
Functional and Display Traits of Terminally
Differentiated Effector Cells
To determine whether T cells specific to the tumor antigens were
functional, we measured their capacity to produce IFN-g and
TNF-a at multiple time points after tumor initiation (Figures 2D
and 2E; Figures S2L–S2M). Very few tumor-reactive T cells in74 Cancer Cell 19, 72–85, January 18, 2011 ª2011 Elsevier Inc.the lungs had the capacity to produce both IFN-g and TNF-a,
and this activity was almost completely lost within the first
5 weeks of tumor development, whereas T cells maintained
production of IFN-g alone (Figure 2D). This pattern of cytokine
production during tumor progression contrasted with the
productive T cell response against WSN-SIY and may indicate
an increase in terminally differentiated effector T cells (IFN-
g+TNF-aneg) that is accompanied by a progressive loss of high-
quality, memory-like T cells (IFN-g+TNF-a+) (Figures 2D and
2E; Figure S2N) (Seder et al., 2008; Wherry et al., 2007). It is
possible that persistent, nonproductive T cell engagement with
tumor antigens drives T cells into an exhausted state (Bucks
et al., 2009; Mueller and Ahmed, 2009; Redmond and Sherman,
2005). Consistent with this, as tumors progressed, tumor-reac-
tive T cells showed increased expression of PD-1, a marker of
T cell exhaustion, and low expression of CD127 (the IL-7Ra
chain), a marker of long-lived memory cells (Figure 2F; not
shown).
Adoptively Transferred T Cells Primed
by Tumors Rapidly Lose Activity
To develop a more detailed view of the dynamics of the T cell
response to established tumors from activation to effector
function, we transferred naive 2C or OT-I TCR transgenic
T cells (which recognize SIY or SIN, respectively) into mice
bearing Lenti-x or Lenti-LucOS tumors. Three days after transfer,
2C and OT-I T cells were activated and proliferated in the lung-
draining lymph nodes and they could be detected in the lungs
12–14 days after transfer (Figures 3A–3C). However, the activity
of these T cells was significantly impaired in the DLN and lungs
compared with T cells responding to the same antigens
expressed in the context of influenza infection (Figure 3D; Fig-
ure S3). Therefore, although T cells can be stimulated to prolif-
erate and migrate to tumors, few T cells retain the capacity to
produce effector cytokines in response to tumors.
Two potential mechanisms may explain the dysfunction
of naive T cells responding to antigens expressed by the Lenti-
LucOS tumors: the presence of an immunosuppressive environ-
ment in tumor-bearing mice or the suboptimal priming of T cells
by antigens expressed in tumors. To test whether the priming of
T cells in the DLN is impaired, we assayed whether T cell activity
in the lungs could be rescued by transferring effector T cells
that were activated in vitro. Indeed, in vitro activated tumor-
specific T cells immediately had the capacity to produce both
IFN-g and TNF-a and maintained this activity in the lungs of
Lenti-LucOS tumor-bearing mice (Figures 3D and 3E). Further-
more, in vitro activated T cells had comparable function in
DLNs to T cells primed in vivo by WSN-SIN (Figure 3E). T cell
activity may be exacerbated by interactions with cells or
secreted factors in the tumor microenvironment. Foxp3+ T regu-
latory cells were found to specifically infiltrate Lenti-LucOS
tumors (Figure S1). Nevertheless, T cell priming by tumor anti-
gens is clearly suboptimal and contributes to the weak antitumor
T cell response.
Antigen Expression and Presentation Is Maintained
in Lenti-LucOS Tumors
The loss of T cell infiltrates in tumors during tumor progression
could also be due to the selection of tumors that lose antigen
A LUNG
0 4 8 12 16 20 24
0.00
0.25
0.50
0.75
anti-SIY
anti-SIN
Weeks post tumor initiation
Pe
rc
en
t o
f l
ym
ph
oc
yt
es
DLN
0 4 8 12 16 20 24
0.00
0.02
0.04
0.06
0.08
Weeks post tumor initiation
Pe
rc
en
t o
f l
ym
ph
oc
yt
es
B
LU
NG
D
LN
Lenti-x Lenti-LucOS WSN-SIY
α-SIN/Kb α-SIN/Kbα-SIY/Kb α-SIY/Kb
C
D
0 4 8 12 16
0
5
10
15
20
25
Weeks post tumor initiation
0 4 8 12 16
0
4
8
12
16 + peptide
no peptide
Weeks post tumor initiation
E
Pe
rc
en
t I
FN
γ+
TN
Fα
+
Pe
rc
en
t I
FN
γ+
TN
Fα
n
e
g
Pe
rc
en
t I
FN
γ+
TN
Fα
+
Lenti-
LucOS
WSN-
SIY
16 weeks
peptide/Kb-PE
pe
pt
id
e/
Kb
-
AP
C
anti-SIY
anti-SIN
5 weeks 8 weeks 16 weeks
LU
NG
PD-1
100 101 102 103 104
0
20
40
60
80
100
100 101 102 103 104
0
20
40
60
80
100
100 101 102 103 104
0
20
40
60
80
100
100 101 102 103 104
0
20
40
60
80
100
10 daysF
DLN
0
25
50
75
100
LUNG LUNG
Gate: CD8+, PI-negative
CD8+α-(SIN or SIY)/Kb +
CD8+α-(SIN or SIY)/Kb neg
Figure 2. T Cell Responses to Tumor Antigens Are Generated but Not Sustained
(A) Representative analysis of SIY and SIN specific CD8+ T cells in the lung and the draining mediastinal lymph node (DLN) of Lenti-x or Lenti-LucOS tumor-
bearing mice or WSN-SIY infected mice using peptide-loaded Kb reagents. FACS plots are gated on PI-negative, CD8+ cells.
(B and C) Percentage of lymphocytes specific for SIN or SIY during Lenti-LucOS tumor progression in the lung or DLN. The percentage of anti-SIN or anti-SIY
reactive cells (of total lymphocytes) was determined as shown in Figure S2A. n = 2–5 mice per time point.
(D) IFN-g and TNF-a cytokine production in SIY and SIN-reactive T cells from the lungs of Lenti-LucOS tumor-bearing mice at several time points after tumor
initiation. The percentage of SIY and SIN-specific T cells from the lungs that were IFN-g+TNF-a+ or IFN-g+TNF-aneg in the absence (no peptide) or in the presence
of SIY and SIN peptides (+ peptide) is shown. Percentages were determined by staining duplicate samples for either DimerX or cytokine production as described
in Figure S2L. n = 2–7 mice per time point.
(E) The percentage of SIY and SIN-specific T cells in the DLN that were IFN-g+TNF-a+ 16weeks after tumor initiation with Lenti-LucOS orWSN-SIY infection. n = 4
mice per group.
(F) PD-1 surface expression on anti-SIY/Kb+ and anti-SIN/Kb+ CD8+ cells (open histograms) or nonspecific CD8+ cells (filled histograms) from the lungs of Lenti-
LucOS tumor-bearing mice at several time points after tumor initiation. n = 2–3 mice per group.
Data are mean ± SEM. See also Figure S2.
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Endogenous T Cell Responses to Lung Adenocarcinomaexpression or antigen presentation to escape the immune
response (Dunn et al., 2002; Khong and Restifo, 2002; Uytten-
hove et al., 1983; Ward et al., 1990; Zhou et al., 2004). To deter-
mine whether the T cell response was driving the outgrowth of
tumors lacking antigen, we compared luciferase activity in
Lenti-LucOS tumors generated in immune-competent and
Rag-2/ mice. At 16 and 20 weeks post tumor initiation, timepoints associated with the dissipation of immune infiltrates in
tumors, luciferase levels were comparable between normal
and immune-compromised mice (Figure 4A). Tumor antigen
presentation in the DLN was maintained during the latest stages
of disease because tumor-specific 2C T cells still proliferated
specifically in the DLN of Lenti-LucOS tumor-bearing mice (Fig-
ure 4B). Lenti-LucOS tumors also maintained higher expressionCancer Cell 19, 72–85, January 18, 2011 ª2011 Elsevier Inc. 75
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Figure 3. Adoptively Transferred T Cells Are Not Fully Functional in Response to Established Tumors
(A) FACS analysis comparing the accumulation of SIN-reactive, OT-I T cells in the mediastinal DLN and the inguinal peripheral lymph nodes (PLN) 3 days after
adoptive transfer of naive OT-I cells into Lenti-x or Lenti-LucOS tumor-bearing mice 10 weeks after tumor initiation (similar results observed 4 weeks after tumor
initiation). Percentage of total CD8+ cells that are anti-SIN/Kb+ is indicated. nR 3 mice for Lenti-LucOS orR 1 mouse for Lenti-x tumor-bearing mice in each of
two independent experiments.
(B) Histogram plots of CD8+anti-SIN/Kb+ gated cells for CFSE dilution or surface expression of CD44, CD62L, or CD69 from the DLN or PLN of Lenti-LucOS (open
histogram) or Lenti-x (filled histogram) tumor-bearing mice. Undivided (CFSEhi) CD8+anti-SIN/Kb+ cells were examined in CD69 plots to detect initial T cell
activation. nR 3 mice for Lenti-LucOS orR1 mouse for Lenti-x tumor-bearing mice in each of two independent experiments.
(C) FACS analysis for the presence of OT-I T cells in the lungs of Lenti-LucOS tumor-bearing mice 12 days after adoptive transfer of naive CD45.1+ OT-I T cells
(tumor-bearing mice were CD45.2+). nR 3 mice in at least three independent experiments.
(D) Percentage of CD8+CD45.1+ gated OT-I T cells producing IFN-g+TNF-a+ or IFN-g+TNF-aneg from the DLN or lung after transfer of naive OT-I T cells. WSN-SIN
represents analysis of OT-I T cells 7 days after WSN-SIN infection. Lenti-LucOS represents analysis of OT-I T cells 12 days after transfer into Lenti-LucOS tumor-
bearing mice between 12 and 16 weeks after tumor initiation. n = 6–7 mice per group.
(E) Percentage of CD8+CD45.1+ gatedOT-I T cells producing IFN-g+TNF-a+ or IFN-g+TNF-aneg from the DLN or lung after transfer of in vitro-activatedOT-I T cells.
Lenti-LucOS represents analysis 1 day (lung only, n = 6 mice) and 12 days after transfer (n = 3 mice) into Lenti-LucOS tumor-bearing mice between 10 and
14 weeks after tumor initiation. WSN-SIN in the DLN represents analysis of naive OT-I T cells 14 days after WSN-SIN infection (n = 3 mice).
Data are mean ± SEM. See also Figure S3.
Cancer Cell
Endogenous T Cell Responses to Lung Adenocarcinomaof MHC class I compared with Lenti-LucOS tumors that arose in
Rag-2/mice or Lenti-x tumors (Figures 4C and 4D). However,
MHC class I expression decreased on Lenti-LucOS tumors
between 16 and 24 weeks after tumor initiation (Figures 4D
and 4E). Reduced MHC class I expression could contribute to
tumor escape and may result from waning antitumor T cell
activity and infiltration into tumors. In support of this hypothesis,
we found that MHC class I expression and SIN presentation on
Lenti-LucOS tumor cell lines were regulated by IFN-g and that
antigen-specific T cell recognition in vitro was sufficient to
upregulate MHC class I and allow for the specific killing of
Lenti-LucOS tumor cells (Figure S4). Therefore, the rapid decline
in T cell infiltration into tumors may result from the combined
effect of reduced antitumor T cell activity that lowers MHC class76 Cancer Cell 19, 72–85, January 18, 2011 ª2011 Elsevier Inc.I expression on tumor cells, ultimately decreasing the potential
for T cells to recognize tumors. This model was supported
in vivo by the antigen-specific retention in Lenti-LucOS tumors
of fully functional in vitro-activated 2C T cells transferred into
tumor-bearing mice 16 weeks after tumor initiation, a time
when few tumors retain endogenous lymphocytic infiltrates
(Figure 4F). Furthermore, by staining tumor sections with the
epithelial marker cytokeratin 8, we could observe tumor-infil-
trating 2C T cells making direct contacts with the epithelial
cancer cells themselves rather than cytokeratin 8-negative
stromal cells (Figures 4G and 4H). Thus, the dissipating T cell
response to Lenti-LucOS tumors during the later stages of tumor
progression is not due to the escape of tumors that lose the
capacity to present the tumor antigens.
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Figure 4. Antigen Expression and Presenta-
tion Is Maintained in Tumors
(A) Luciferase activity (RLU/mg protein) in
tumor lysates from K-rasLSL-G12D/+;p53fl/fl or
K-rasLSL-G12D/+;p53fl/fl;Rag-2/ mice at 16 or
20 weeks after tumor initiation. n = 8–14 tumors
per mouse per group.
(B) FACS analysis comparing the accumulation of
SIY-reactive, 2C T cells in the DLN 3 days after
adoptive transfer of naive 2C cells into Lenti-x
(n = 1) or Lenti-LucOS (n = 3) tumor-bearing mice
24 weeks after tumor initiation. CFSE dilution of
CD8+1B2+ cells in mice with Lenti-LucOS (open
histogram) or Lenti-x (filled histogram) tumors.
(C) Freshly isolated Lenti-LucOS tumors generated
in Rag-2null (dashed line) and Rag-2+ mice (solid
line) 20 weeks after tumor initiation were pooled
and compared by FACS analysis for H-2Kb surface
expression after gating-out cells positive for CD45,
CD31, Ter119, and IA/IE (MHCII). Plots represen-
tative of three pooled tumor samples from Rag-
2null or Rag-2+ mice. Filled histogram is a negative
control stain for CD8.
(D) Freshly isolated Lenti-LucOS (solid line) and
Lenti-x tumors (dashed line) at 16 and 24 weeks
after tumor initiation compared by FACS analysis
for H-2Kb surface expression as in (C). Plots repre-
sentative of pooled and individual tumor samples
from two independent experiments. Filled histo-
grams are negative control stains for H-2Kd.
(E) H-2Kb mean fluorescent intensity on Lenti-
LucOS and Lenti-x tumors at 16 and 24 weeks
after tumor initiation. n = 2–3 mice, 6–11 tumor
samples per group per time point.
(F) Activated 2C T cells, or a-CD3/CD28 activated
polyclonal CD8+ T cells, labeled with CFSE were
transferred into Lenti-LucOS or Lenti-x tumor-
bearing mice 16 weeks after tumor initiation and
tumors were analyzed for the presence of CFSE+
cells (green) 24 hr later. DAPI counter stained.
Tumors are outlined and quantification of the
number of CFSE+ cells/tumor is indicated. Scale =
50 mm. n = 2–4 mice, 21–38 tumors, per group.
(G) Cytokeratin 8 (red) stained Lenti-LucOS tumors
from (F) that received activated CFSE+ 2C T cells
(green) 16 weeks after tumor initiation. Scale =
50 mm.
(H) High magnification of box outlined in (G).
Scale = 10 mm.
Data are mean ± SEM. See also Figure S4.
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Endogenous T Cell Responses to Lung AdenocarcinomaImmunogenic Tumors Exhibit Delayed
Tumor Progression
Despite the suboptimal antitumor T cell response, it remained
possible that the immune response might still affect the course
of the disease. To understand the impact of the T cell response
on tumor progression, we first compared the size of ‘‘immuno-
genic’’ Lenti-LucOS tumors to ‘‘nonimmunogenic’’ Lenti-x
tumors over the lifespan of tumor-bearing mice. As shown in
Figure 5, at each time point examined, immunogenic tumors
were smaller than nonimmunogenic tumors, with the differences
in size being most significant at 8 and 16 weeks after tumor
initiation, coincident with T cell infiltration into tumors (Figure 5A).Analysis of tumors 8 weeks after initiation revealed an increase in
apoptosis in Lenti-LucOS compared with Lenti-x tumors but no
difference in proliferation (Figures S5A and S5B). Importantly, the
difference in size between Lenti-LucOS and Lenti-x tumors
required the presence of the adaptive immune system, because
the expression of the LucOS antigens had no effect on tumor size
when induced in Rag-2/ mice (Figure 5B). We also followed
tumor progression by examining the histological tumor grades
at each time point. At 8 and 16 weeks after tumor initiation,
Lenti-LucOS tumors were of lower grade compared with Lenti-
x tumors (Figure 5C). By 24 weeks after tumor initiation, the
primary lung tumor grades were similar; however, far fewerCancer Cell 19, 72–85, January 18, 2011 ª2011 Elsevier Inc. 77
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Figure 5. Immunogenic Tumors Have De-
layed Tumor Progression
(A) Tumor area of Lenti-LucOS and Lenti-x lung
tumors at 8, 16, and 24 weeks after tumor initia-
tion. p values are 1010, 1014, and 0.108,
respectively, from n = 9–15 mice, 44–892 tumors,
per group.
(B) Tumor area of Lenti-LucOS and Lenti-x lung
tumors in K-rasLSL-G12D/+;p53fl/fl;Rag-2/ mice
16 weeks after tumor initiation. p 0.561 from
n = 6–7 mice, 45–223 tumors, per group.
(C) Tumor grades for Lenti-LucOS and Lenti-x lung
tumors at 8, 16, and 24 weeks after tumor initia-
tion. n = 9–22 mice, 49–1594 tumors, per group.
(D) The number of lung tumors/mouse and meta-
static index (number of mice with detectable
metastases/total examined, p < 0.02) in Lenti-
LucOS and Lenti-x tumor-bearing mice 24 weeks
after tumor initiation. n = 8–12 mice per group.
(E) Kaplan-Meier plot comparing the survival of
Stage I/II (lymph node metastases free, N0) lung
adenocarcinoma patients with high or low CD3
expression in tumors. Patients were ranked from
highest to lowest based on CD3 expression in
tumors (average expression of CD3d, CD3g,
CD33, and CD247 (CD3z)) and the top versus
bottom quartiles were compared, p < 0.02.
Data are mean ± SEM. See also Figure S5.
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Endogenous T Cell Responses to Lung Adenocarcinomamice with immunogenic tumors had metastatic disease (Fig-
ure 5D). Thus, early antitumor T cell responses can have long-
lasting effects on tumor progression that delay the most deadly
phase of the disease. Analysis of human lung adenocarcinoma
gene expression datasets indicated that high expression of
CD3 genes in tumor samples, as well as other genes expressed
specifically in T and B cells, was predictive of better patient
outcomes (Figure 5E; Figures S5C–S5F).
Loss of Antigen Expression in Transplantable
Models of Lung Cancer
Tumor antigen loss has been reported as a mechanism of tumor
immune evasion in transplantable models of cancer (Spiotto78 Cancer Cell 19, 72–85, January 18, 2011 ª2011 Elsevier Inc.et al., 2004; Uyttenhove et al., 1983;
Ward et al., 1990; Zhou et al., 2004). Since
the endogenously arising lung tumors did
not lose antigen expression or presenta-
tion in the face of an antitumor immune
response, we hypothesized that this
may be the consequence of a weaker
immune response against endogenous
tumors compared with transplanted
tumors. To compare immune responses
in the context of transplantable or endog-
enously arising models of cancer, we
transduced cell lines from the K-rasG12D-
driven lung tumor model with lentiviral
vectors to introduce either SIY fused to
luciferase (LKR10-LucS) or ovalbumin
(containing SIN and OVA323-339) and SIY
fused to luciferase (LKR13-LucOS), andtransplanted the cell lines subcutaneously into syngeneic
immune-competent mice (Figure S4A). While the parental
LKR10 and LKR13 cell lines produced tumors upon transplanta-
tion, the antigen-expressing LKR10-LucS and LKR13-LucOS
were rejected or exhibited delayed growth and generated
CD8+ T cells specific to SIN and/or SIY (Figures 6A and 6B;
Figures S6A–S6D). In stark contrast to the situation with autoch-
thonous tumors, all the tumors that grew in immune-competent
mice lost expression of the antigens (Figure 6C). Transferring
naive 2C or OT-I T cells into immune-compromisedmice bearing
established LKR10-LucS or LKR13-LucOS tumors led to reduc-
tions in tumor volume and antigen expression in an antigen-
specific manner (Figures 6D and 6E). Thus, T cell responses to
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Figure 6. Transplanted Lung Tumors Induce Strong T Cell Responses that Force Tumor Elimination or Tumor Antigen Loss
(A) Number of tumors rejected of the total transplanted subcutaneously into immune-competent or immune-compromised (Rag-2null) 129S4/SvJae mice (n.d. =
not done). Results are cumulative from three independent experiments and transplantation of 105–106 cells.
(B) Size of LKR13 and LKR13-LucOS tumors 8 and 27 days after subcutaneous transplantation into immune-competent 129S4/SvJae mice or LKR13-LucOS into
Rag-2null 129S4/SvJaemice. LKR13-LucOS tumors that were rejected are not included. Results are cumulative from three independent experiments. n = 2–5mice
per group.
(C) Representative in vivo luciferase activity of LKR10-LucS or LKR13-LucOS tumors transplanted subcutaneously into Rag-2+ or Rag-2null 129S4/SvJae mice.
(n = 23 mice, 6–7 LKR10-LucS, 4–6 LKR13-LucOS per group).
(D) Tumor growth after subcutaneous transplantation of LKR10-LucS or LKR13-LucOS into Rag-2null mice followed by transfer of naive OT-I or 2C T cells (arrow)
and measurement of luciferase activity (star) (OTI/2C = OT-I or 2C transfer). n = 3–4 mice per group.
(E) Representative in vivo luciferase activity of LKR10-LucS tumors in Rag-2null mice that received OT-I or 2C T cells from (D). All LKR13-LucOS tumors lost
detectable luciferase activity with transfer of OT-I or 2C T cells.
(F) Representative in vivo luciferase activity 7 and 14 days after subcutaneous transplantation of a Lenti-LucOS induced lung tumor cell line (KP-LucOS.3) into
Rag-2null or Rag-2+ 129S4/SvJae mice.
(G) Similar to (D), Lenti-LucOS induced lung tumor cell lines (KP-LucOS.3 and KP-LucOS.2) or LKR13-LucOS were transplanted subcutaneously into Rag-2null
mice, then OT-I, 2C, or no T cells were transferred and luciferase activity was measured in tumor cell lines generated from the tumors >28 days after transplan-
tation.
(H) Lenti-LucOS induced lung tumor cell lines were orthotopically transplanted into 129S4/SvJae mice and luciferase activity in the grafted lung tumors was
assayed and compared to the activity before transplantation (f = not detectable).
Data are mean ± SEM. See also Figure S6.
Cancer Cell
Endogenous T Cell Responses to Lung Adenocarcinomaa single antigen expressed in transplanted lung tumor cell lines
are sufficient to elicit tumor rejection or induce the selective
outgrowth of tumors that lose antigen expression.
It has been reported that spontaneous tumors induce a state
of systemic tolerance such that T cells can no longer respond
to transplanted tumors (Willimsky and Blankenstein, 2005). In
this model, however, mice bearing autochthonous lung tumors
expressing model tumor antigens still produced effective T cell
responses against transplanted tumors expressing the sameantigens (Figure S6E). We suspect that leaky expression of
tumor antigens in normal tissues, rather than tumor-specific
expression, may be responsible for the systemic tolerance to
tumor antigens in these transgenic models (Bai et al., 2008;
Cheung et al., 2008; Drake et al., 2005; Willimsky and Blanken-
stein, 2005).
Finally, Lenti-LucOS cell lines, derived from autochthonous
lung tumors that had escaped the immune response in situ
without losing antigen expression, lost antigen expression inCancer Cell 19, 72–85, January 18, 2011 ª2011 Elsevier Inc. 79
Cancer Cell
Endogenous T Cell Responses to Lung Adenocarcinomaa T cell-dependent manner when transplanted subcutaneously
into immune-competent mice (Figures 6F and 6G). These cell
lines also lost antigen expression after orthotopic transplantation
into the lung, indicating that transplantation, even into a tumor’s
native site, can induce T cell responses that drive tumor antigen
loss (Figure 6H).
Enhancing the Antitumor T Cell Response
with Vaccination Causes Tumor Elimination
and Tumor Antigen Loss
Enhanced T cell priming in the context of transplanted tumors is
a likely explanation for tumor elimination and tumor antigen loss
in this setting. Therefore, priming by vaccination might elicit
similar antitumor T cell responses against autochthonous
tumors. To examine this possibility, we vaccinated mice prophy-
lactically with a dendritic cell line engineered to express the
LucOS antigens (DC2.4-LucOS) and subsequently induced
Lenti-LucOS or Lenti-x tumors. Vaccination did not affect the
number of Lenti-x tumors, but dramatically reduced the number
of Lenti-LucOS tumors and antigen expression in tumors that
formed (Figures 7A–7C). This was likely due to an enlarged
T cell response early during tumor development, as well as
a functionally enhanced response characterized by increased
secretion of effector proteins and the maintenance of CD127+
memory-like cells (Figures 7D–7F).
Despite the dramatic reduction of antigen expression in Lenti-
LucOS tumors from vaccinated mice, there were still significant
numbers of tumor-infiltrating lymphocytes 8 weeks after tumor
initiation. Interestingly, in vitro-activated T cells specific to
the model antigens could still recognize Lenti-LucOS tumors
in DC2.4-LucOS vaccinated mice after adoptive transfer
(Figure 7G). The maintenance of a T cell response to the tumor
antigens in vaccinated mice led us to ask whether the progres-
sion of Lenti-LucOS tumors was altered in vaccinated compared
with unvaccinated mice. Although Lenti-LucOS tumors in vacci-
nated mice appeared only modestly smaller 16 weeks after
tumor initiation, the differences in tumor size between vacci-
nated and unvaccinatedmice increased at 24 and 30weeks after
tumor initiation (Figure 7H; Figure S7A). The delayed tumor
growth in vaccinated mice correlated with a prolonged retention
of lymphocytic infiltrates into tumors (Figure 7I; Figure S7B),
again highlighting the potential for tumor-infiltrating lymphocytes
to delay tumor progression.
DISCUSSION
Several important conclusions regarding immune-tumor interac-
tions and their role in regulating tumor progression are evident
from our study that could not be directly addressed using
previous cancer models. Thus far, using genetically engineered
mouse models, it has not been possible to compare tumors
expressing or lacking tumor-specific antigens (Clark et al.,
2007; Huijbers et al., 2006; Willimsky and Blankenstein, 2005).
With the recent sequencing of several cancer genomes,
including lung adenocarcinomas, it is clear that human tumors
contain hundreds of mutated proteins and many of these have
the potential to be presented on MHC molecules, thus providing
a means for T cells to recognize tumors as distinct from their
surrounding normal tissues (Ding et al., 2008; Segal et al.,80 Cancer Cell 19, 72–85, January 18, 2011 ª2011 Elsevier Inc.2008; Sjoblom et al., 2006). Our ability to specifically control
the induction of tumor formation and tumor antigen expression
has allowed us to closely recapitulate the effects of T cell
responses to tumor-specific antigens from inception to malig-
nant transformation.
In contrast to transgenic models of tumor-associated antigen
expression, here we followed endogenous T cell responses
against antigens expressed in autochthonous lung tumors in
an attempt to model T cell responses to tumor neoantigens. By
tracking the response of endogenous T cells as well as trans-
ferred T cells, we find that suboptimal T cell responses against
tumors are not necessarily due to immune ignorance (Nguyen
et al., 2002; Ochsenbein et al., 2001; Speiser et al., 1997; Spiotto
et al., 2002). However, the expansion of T cells specific to the
tumor antigens was markedly delayed, potentially allowing
tumor escape (Hanson et al., 2000; Ochsenbein et al., 2001),
and the T cell response eventually declined in both magnitude
and quality as tumors progressed. Despite their ability to prolif-
erate and migrate to tumors, T cells had an altered phenotypic
state that was exemplified by a poor capacity to produce and
secrete effector cytokines and a rapid loss of TNF-a production
in the lung. The reduced capacity of T cells to produce effector
cytokines such as IFN-g and TNF-a as tumors progressed
may account for their inefficient migration to tumors over time
(Calzascia et al., 2007; Muller-Hermelink et al., 2008). The ability
to precisely time tumor initiation revealed a dynamic relationship
between antitumor T cells and tumor cells. Loss of T cell activity
can contribute to the rapid decline in tumor-infiltrating lympho-
cytes by allowing for reduced MHC class I expression on tumor
cells. Tumor-reactive T cells were also found to express high
levels of PD-1 and low levels of CD127, features that resemble
T cell responses during chronic infections (Bucks et al., 2009;
Wherry et al., 2007). Indeed, the T cell response to lung tumors
was quite distinct from the response to the same antigens
expressed by recombinant influenza virus after infection of the
lung. Signaling through the inhibitory PD-1/PD-L1 pathway alone
was not responsible for the loss of T cell reactivity against tumors
in this model because blocking the function of this pathway with
the use of antibodies or PD-1-deficient T cells did not rescue the
activity of tumor-reactive T cells (not shown). Instead, T cell
exhaustion might be exacerbated by an ineffective antitumor
immune response that allows prolonged T cell exposure to
antigens expressed from tumors. Chronic T cell stimulation
with cognate antigen has been shown to be sufficient to drive
exhaustion in several settings (Bucks et al., 2009; Drake et al.,
2005; Mueller and Ahmed, 2009; Redmond and Sherman,
2005). We also found that T regulatory cells were recruited
specifically to tumors expressing the LucOS antigens, and
T regulatory cells have been shown to suppress antitumor
responses in several cancer models (Clark et al., 2007; Ercolini
et al., 2005; Pellegrini et al., 2009). Despite the evidence of an
incomplete antitumor T cell response, the immune response still
delayed tumor progression, indicating that suboptimal T cell
responses that do not eliminate tumors are capable of slowing
cancer progression (Koebel et al., 2007). This mirrors observa-
tions made here and in several retrospective studies of human
cancer patients in which immune infiltration into tumors signifi-
cantly correlated with improved patient outcomes (Buckanovich
et al., 2008; Budhu et al., 2006; Dunn et al., 2002; Finak et al.,
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Figure 7. Vaccination in Autochthonous Lung Tumor Model Reduces Tumor Burden and Promotes Loss of Antigen Expression
(A and B) Tlumor number on the lungs of mice with Lenti-x or Lenti-LucOS tumors 16 weeks after tumor initiation with or without prior DC2.4-LucOS vaccination.
p values are 0.50 and 0.0008, respectively.
(C) Freshly explanted Lenti-LucOS tumors were assayed for luciferase activity and the percentage of tumors that were luciferase positive (>50 RLU/mg protein) ±
DC2.4-LucOS vaccination is plotted. n = 5–6 mice, 27–34 tumors, per group.
(D) Representative FACS plots of SIY/Kb-specific T cells (gated on CD8) from the lung and DLN ± DC2.4-LucOS vaccination, 9 days after tumor initiation with
Lenti-LucOS. nR 2 mice per group.
(E) FACS for surface-exposed CD107a and captured IFN-g (gated on CD8) after stimulation of DLN cells with SIY and SIN from Lenti-LucOS or Lenti-x tumor-
bearingmice ±DC2.4-LucOS vaccination (16weeks post tumor initiation). Mean fluorescent intensities of CD107a and IFN-g on reactive T cells from Lenti-LucOS
tumor-bearing mice is plotted. n = 2–4 mice per group.
(F) FACS analysis of CD8+ anti-SIY/Kb+- and anti-SIN/Kb+-specific T cells for CD127 andCD44 surface expression from the lungs or DLNof Lenti-LucOS or Lenti-x
tumor-bearingmice±DC2.4-LucOSvaccination (8weekspost tumor initiation, n =2–3miceper group). The ratio ofCD44+CD127+ (memory-like) toCD44+CD127-
(effector-like) is shown below each FACS plot.
(G) Lenti-LucOS tumors from mice 8 weeks after tumor initiation and 24 hr after transfer of SIY-reactive, CFSE-labeled activated T cells (green) ± DC2.4-LucOS
vaccination. DAPI counter stained. Tumors are outlined. Scale = 50 mm.
(H) Mean tumor area of Lenti-LucOS lung tumors at 16, 24, and 30 weeks after tumor initiation ± DC2.4-LucOS vaccination. p values are 0.050, 0.038, and
0.027, respectively, from n = 3–10 mice, 70–506 tumors, per group at 16 and 24 weeks, and n = 1–2 mice, 15–46 tumors, per group at 30 weeks.
(I)PercentageofLenti-LucOStumors/mousecontaining infiltrating lymphocytesat16,24,and30weeksafter tumor initiation±DC2.4-LucOSvaccination (analysisofmicefrom(H).
Data are mean ± SEM. See also Figure S7.
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Prophylactic vaccination provided substantial protection from
autochthonous tumors, but it also led to prolonged immune
infiltration into the Lenti-LucOS tumors, further delaying tumor
progression even though antigen expression was dramatically
reduced. Delayed tumor progression despite antigen loss may
occur through direct targeting of tumor cells by T cells or via indi-
rect elimination of tumor cells during T cell-mediated destruction
of stromal cells that cross-present tumor antigens in the tumor
microenvironment (Spiotto et al., 2004). This result has important
implications for immunotherapy because it indicates that gener-
ating large numbers of highly functional, tumor-reactive T cells
that persist long-term can effectively inhibit tumor progression
even after the selective outgrowth of tumors that express very
low levels of the targeted antigen.
The majority of studies investigating immunity to cancer have
focused on transplantable models of cancer (Dunn et al., 2002;
Hanson et al., 2000; Khong and Restifo, 2002; Koebel et al.,
2007; Ochsenbein et al., 2001; Schreiber, 2003; Shankaran
et al., 2001; Spiotto et al., 2002; Street et al., 2002; Thomas
and Massague, 2005). These studies have led to the discovery
of several important mechanisms in both T cells and tumor cells
that can modulate the effectiveness of antitumor T cell
responses or allow for tumor escape. However, these models
may not accurately reflect the human disease (Khong and
Restifo, 2002). Here, we have used comparable models of
transplantable and autochthonous lung cancer to show that
transplantation induces antitumor T cell responses capable of
driving tumor immunoediting. Even orthotopic transplantation
of cell lines derived from Lenti-LucOS-induced tumors that had
escaped immune surveillance in their autochthonous setting
led to an adaptive immune response that forced the outgrowth
of tumors with reduced antigen expression, a phenomenon
that never occurred with autochthonous tumors expressing
these antigens. This was due in part to suboptimal priming of
T cells in the context of autochthonous tumors. T cells activated
in vitro had enhanced activity compared with T cells stimulated
in vivo and priming of T cells by vaccination led to responses
against autochthonous tumors that were comparable to
responses against transplanted tumors. From our comparison
of autochthonous and transplanted tumors, we conclude that
the immune system recognizes tumors that originate from trans-
formation of somatic cells in an inherently different way than
transplanted tumor cell lines.
Future experiments should address the diversity of antitumor
immune responses that likely stem from subtle differences in
the models used for the investigations. The development of
models that link the tumor antigen to the driving oncogenic event
will be useful for investigating whether T cell responses to onco-
genic antigens, whose expression in tumors cannot easily be
downregulated to evade an immune response, instigate alterna-
tive mechanisms of tumor escape (Willimsky and Blankenstein,
2005). Models in which tumor initiation and expression of
tumor-specific antigens are temporally separable may discern
whether T cell responses are different if the induction of antigen
expression occurs in established tumors, where mutated
proteins most likely arise in human cancers. Indeed, using these
lentiviral vectors to initiate tumor development and introduce the82 Cancer Cell 19, 72–85, January 18, 2011 ª2011 Elsevier Inc.antigens has some important limitations. Specifically, these
lentiviruses require viral infection concomitant with tumor initia-
tion, and they cannot completely restrict the expression of the
antigens to tumor cells. However, preliminary experiments with
lentiviral systems that can restrict the expression of the antigens
to lung epithelial cells, as well as experiments in which we
delayed antigen expression to several days after the lentiviral
infection, indicate that inducing the expression of these antigens
in lung epithelial cells is sufficient to generate antigen-specific
T cell responses. Further investigation is necessary to determine
whether priming during tumor initiation in the context of the
lentiviral infection alters the outcome of the antitumor immune
response. Finally, discoveries made in a particular model of
cancer have often been accepted as broadly applicable to all
immune-tumor interactions. However, the immune response
and tumor response are likely to vary greatly depending on the
originating tissue and the genetic pathology of the disease.
Therefore, it will be important to extend these analyses to other
genetically engineered mouse models of cancer to discern
whether T cell responses and tumor development change
depending on the context of the disease.
EXPERIMENTAL PROCEDURES
Mice and Tumor Induction
129S4/SvJae strains backcrossed 8 generations were used for all tumor
transplant experiments and most autochthonous tumor studies. C57/BL6
mice backcrossed five generations were used when transgenic T cells from
C57/BL6 mice were adoptively transferred (Figures 3 and 4B). Trp53fl mice
were provided by A. Berns, K-rasLSL-G12D were generated in our laboratory,
andRag-2/micewere purchased from The Jackson Laboratory (Bar Harbor,
ME). Lung tumors were induced in K-rasLSL-G12D/+;p53fl/flmice by intratracheal
intubation and inhalation of viruses expressing Cre recombinase as reported
(DuPage et al., 2009). J. Chen provided the 2C, OT-I, and OT-II TCR transgenic
mice that were C57/BL6 and crossed into Rag-2/. All animal studies and
procedures were approved by the Massachusetts Institute of Technology’s
Committee for Animal Care.
Lentiviral Production
Lentiviruses were produced by transfection of 293T cells with D8.2 (gag/pol)
and CMV-VSV-G as described (DuPage et al., 2009).
Histology, Tumor Size, Tumor Grading
Mice were killed at designated time points and lung tissues were preserved by
fixation with 3.6% formaldehyde solution or frozen in O.C.T. Bioquant Image
Analysis software was used to measure the area of individual tumors in histo-
logical sections. Grading was performed by R.B. as described (DuPage et al.,
2009). Metastasis was monitored by gross examination of mice at necropsy
and histological examination of lung DLNs.
Immunohistochemistry
We performed immunohistochemical analysis on formalin-fixed paraffin
sections after heat-mediated antigen retrieval in sodium citrate (see
Abcam protocol). We used a-CD3 (1:100, Dako), a-B220 (1:50, RA3-6B2),
a-Mac-3 (1:10, M3/84) (BD PharMingen), a-Foxp3 (1:25, FJK-16s)
(eBioscience), a-cytokeratin 8 (1:25) primary antibodies and Vectastain ABC
secondary reagents followed by DAB substrate detection (Vector
Laboratories).
Flow Cytometry
Cell suspensions from lymphoid organs were prepared by mechanical disrup-
tion between frosted slides or from lungs by mincing and digesting the tissues
for 1 hr at 37C in 125 U/ml Collagenase Type I (GIBCO) and 60 U/ml
Hyaluronidase (Sigma). Cells were stained with antibodies for 20–30 min after
Cancer Cell
Endogenous T Cell Responses to Lung Adenocarcinomatreatment with FcBlock (BD PharMingen). a-CD8a (53-6.7), a-CD45.1 (A20),
a-mouse IgG1 (X56), a-PD-1 (J43), a-IFN-g (XMG1.2), a-TNF-a (MP6-XT22),
a-CD107a (ID4B), a-CD44 (IM7), a-CD62L (MEL-14), a-CD69 (H1.2F3), and
DimerX I (Dimeric Mouse H-2Kb:Ig) were from BD PharMingen. a-CD127
(A7R34) was from eBioscience. J. Chen provided the 1B2 antibody recog-
nizing the 2C TCR. H. Eisen provided the 25-D1.16 antibody that recognizes
SIN-loaded Kb/MHCI. All antibodies were used at 1:200. Peptide-loaded
DimerX reagents were prepared as directed and used at 1:75. To improve
the sensitivity of the DimerX reagent, we utilized both PE and APC labeled
dimers to costain CD8+ T cells. Propidium iodide was used to exclude dead
cells. Cells were read on a FACSCalibur or LSR II (BD Biosciences) and
analyzed using Flowjo software (Tree Star).Cytokine Production
Cells were resuspended in the presence or absence of SIYRYYGL and/or
SIINFEKL peptides in OPTI-MEM I (GIBCO) supplemented with GolgiPlug
(BD PharMingen) for4 hr at 37C, 5%CO2. Cells were then fixed and stained
for intracellular cytokines using the Cytofix/Cytoperm kit (BD Biosciences). For
IFN-g capture, cells were stained with the capture and detection antibodies as
directed (Miltenyi Biotec).Luciferase Detection
Freshly explanted tumors or cell lines were lysed in Cell Culture Lysis Reagent,
mixed with Luciferase Assay Reagent (Promega), and relative light units (RLU)
were detected using the Optocomp I luminometer (MGM Instruments). RLUs
were standardized based on the total number of cells or total protein (Bio-
Rad Protein Assay). In vivo bioluminescence images were obtained using
the NightOWLII LB983 (Berthold Technologies) after intraperitoneal injection
of 1.5 mg Beetle Luciferin (Promega).CFSE Labeling and Adoptive Transfer
Naive and activated T cells were labeled with 5 mM CFSE (Molecular Probes)
for 10min at 37C. Naive TCR transgenic T cells were harvested from lymphoid
organs, stained, and 5 3 105–106 CD8+ cells were transferred intravenously.
Activated TCR transgenic cells were stimulated in vitro with cognate peptide
for 16–20 hr and then cultured for 6–7 days in complete-RPMI supplemented
with 5 ng/ml IL-2 (R&D Systems). 107 in vitro-activated T cells were transferred
intravenously.Tumor Cell Lines and Transplantation
LKR10 and LKR13 cell lines were derived from K-rasG12D-driven mouse lung
tumors from 129S4/SvJae mice. LKR10-LucS and LKR13-LucOS were gener-
ated by lentiviral infection with LucS or LucOS constructs (no Cre). KP-LucOS
and KP-x cell lines were derived from Lenti-LucOS- or Lenti-x-induced lung
tumors, respectively, from 129S4/SvJae mice. Cells (10
5–106) were trans-
planted subcutaneously (sc) or intravenously (for orthotopic). 129S4/SvJae
immune-competent and Rag-2/ transplant recipients came from the same
mouse strains used to generate the autochthonous tumors. Sc tumor volumes
were calculated by multiplying length 3 width 3 height of each tumor.DC2.4-LucOS Vaccination
DC2.4-LucOS cells were generated from the dendritic cell line (DC2.4) after
infection with lentivirus that expresses LucOS (no Cre). Mice were vaccinated
by intraperitoneal injection of 5 3 105 cells >1 month prior to tumor initiation.Influenza
WSN-SIY and WSN-SIN were provided by J. Chen. Mice were infected with
20 pfu of virus by intratracheal inhalation.Statistical Analyses
P values from unpaired two-tailed Student’s t tests were used for statistical
comparisons with the following exceptions: Figure 7F utilized Welch’s
correction, Figure 5D utilized the Fischer exact probability test, and Figure 5E
utilized the log rank test.SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, Supplemental Experimental
Procedures, and Supplemental References and can be found with this article
online at doi:10.1016/j.ccr.2010.11.011.
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